Treatment of Inherited Platelet Disorders: Current Status and Future Options

Area of Science:

• Hematology
• Genetics
• Internal Medicine

Background:

• Inherited platelet disorders (IPDs) are a diverse group of conditions causing varied bleeding issues.
• Effective management necessitates considering the specific platelet disorder, bleeding characteristics, and patient demographics.
• Existing guidelines require updates to incorporate new treatment modalities and clinical scenarios.

Purpose of the Study:

• To evaluate the validity of previous AWMF S2K guideline #086-004.
• To supplement existing information with current and future treatment options for IPDs.
• To address specific clinical challenges, including menorrhagia and pregnancy management in women with IPDs.

Main Methods:

• Review and evaluation of existing AWMF S2K guideline #086-004.
• Inclusion of data on newly available and emerging treatment options.
• Analysis of clinical scenarios requiring specific management strategies.

Main Results:

• Established treatments include local hemostasis, tranexamic acid, desmopressin, platelet transfusions, and recombinant activated factor VII.
• Hematopoietic stem cell therapy offers a curative option for select patients.
• Promising future therapies include autologous stem cell gene therapy, artificial platelets, nanoparticles, and other procoagulant agents.

Conclusions:

• Updated management strategies for IPDs are crucial, integrating established and novel therapeutic approaches.
• Special attention to menorrhagia and pregnancy risks in women with IPDs is warranted.
• Ongoing research into advanced therapies holds significant promise for improving IPD patient outcomes.